Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. The company announced data from its Phase 1 clinical study of its Gemini treatment. These results were extremely positive and represent a major step forward for Revelation.
